Repligen Corporation(RGEN)Earnings, Financials & Key Ratios

RGEN•NASDAQ

$125.76

$7.09B mkt cap·146.2× P/E·Price updated May 6, 2026

SectorHealthcare IndustryMedical Instruments Sub-IndustryDiagnostics and life science tools

AboutRepligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Show more

Revenue$738M+16.4%
EBITDA$138M+168.9%
Net Income$49M+291.6%
EPS (Diluted)0.86+287.0%
Gross Margin47.09%+8.8%
EBITDA Margin18.74%+131.1%
Operating Margin8.07%+245.8%
Net Margin6.62%+264.7%
ROE2.4%+285.0%
ROIC2.16%+257.2%
Debt/Equity0.33-5.8%
Interest Coverage3.69+1422.1%

Technical→

RGEN Key Insights

Repligen Corporation (RGEN) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 15.0%
✓Healthy 5Y average net margin of 10.1%

✗Weaknesses

✗Weak 3Y average ROE of 1.0%
✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

RGEN Price & Volume

Repligen Corporation (RGEN) stock price & volume — 10-year historical chart

Loading chart...

RGEN Growth Metrics

Repligen Corporation (RGEN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years24.35%

5 Years15.05%

3 Years-2.7%

TTM17.36%

Profit CAGR

10 Years18%

5 Years-3.99%

3 Years-35.94%

TTM323.66%

EPS CAGR

10 Years11.88%

5 Years-4.98%

3 Years-35.73%

TTM842.57%

Return on Capital

10 Years10%

5 Years4.63%

3 Years0.95%

Last Year2.16%

RGEN Recent Earnings

Repligen Corporation (RGEN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)

Q2 2026Latest

May 5, 2026

EPS

$0.48

Est $0.38

+26.3%

Revenue

$194M

Est $192M

+1.1%

Q1 2026

Feb 24, 2026

EPS

$0.49

Est $0.44

+11.4%

Revenue

$198M

Est $193M

+2.6%

Q4 2025

Oct 28, 2025

EPS

$0.46

Est $0.42

+9.5%

Revenue

$189M

Est $192M

-1.8%

Q3 2025

Jul 29, 2025

EPS

$0.37

Est $0.40

-7.5%

Revenue

$182M

Est $182M

+0.3%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 5, 2026	$0.48vs $0.38+26.3%	$194Mvs $192M+1.1%
Q1 2026	Feb 24, 2026	$0.49vs $0.44+11.4%	$198Mvs $193M+2.6%
Q4 2025	Oct 28, 2025	$0.46vs $0.42+9.5%	$189Mvs $192M-1.8%
Q3 2025	Jul 29, 2025	$0.37vs $0.40-7.5%	$182Mvs $182M+0.3%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
FTREFortrea Holdings Inc.Direct Competitor	1.46B	15.64	-1.45	1%	-16.5%	-79.12%	0.12
NTRANatera, Inc.Direct Competitor	29.58B	215.09	-140.58	56.75%	-14.61%	-24.69%	0.16
AZTAAzenta, Inc.Direct Competitor	846.61M	18.38	-15.07	3.55%	-29.86%	-10.69%	0.06
BRKRBruker CorporationDirect Competitor	6.44B	42.30	-282	2.08%	-0.75%	-1.11%	0.81
NVCRNovoCure LimitedDirect Competitor	1.88B	16.50	-13.52	8.28%	-25.66%	-50.82%	0.85
ACADACADIA Pharmaceuticals Inc.Direct Competitor	3.68B	21.48	9.38	11.87%	36.49%	41.9%	0.04
CRLCharles River Laboratories International, Inc.Product Competitor	8.97B	181.73	-62.45	-0.85%	-3.59%	-4.34%	0.95
ICLRICON Public Limited CompanyProduct Competitor	9.48B	124.13	13.03	1.99%	7.4%	6.32%	0.38

Compare RGEN vs Peers

Repligen Corporation (RGEN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs FTRE

Most directly comparable listed peer for RGEN.

Scale Benchmark

vs TMO

Larger-name benchmark to compare RGEN against a more recognizable public peer.

Peer Set

Compare Top 5

vs FTRE, NTRA, AZTA, BRKR

RGEN Income Statement

Repligen Corporation (RGEN) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	141.24M	194.03M	270.25M	366.26M	670.53M	801.54M	632.36M	634.44M	738.26M	763.34M
Revenue Growth %	35.1%	37.38%	39.28%	35.53%	83.08%	19.54%	-21.11%	0.33%	16.36%	17.36%
Cost of Goods Sold	67.05M	85.95M	132.02M	171.91M	279.28M	345.83M	353.92M	359.79M	390.63M	283.98M
COGS % of Revenue	47.47%	44.3%	48.85%	46.94%	41.65%	43.15%	55.97%	56.71%	52.91%	-
Gross Profit	74.19M▲ 0%	108.08M▲ 45.7%	138.22M▲ 27.9%	194.35M▲ 40.6%	391.25M▲ 101.3%	455.71M▲ 16.5%	278.44M▼ 38.9%	274.64M▼ 1.4%	347.62M▲ 26.6%	393.38M▲ 0%
Gross Margin %	52.53%	55.7%	51.15%	53.06%	58.35%	56.85%	44.03%	43.29%	47.09%	51.53%
Gross Profit Growth %	29.19%	45.69%	27.89%	40.61%	101.31%	16.47%	-38.9%	-1.36%	26.57%	-
Operating Expenses	60.18M	82.09M	98.14M	113.07M	224M	231.04M	230.74M	309.76M	288.05M	326.82M
OpEx % of Revenue	42.61%	42.31%	36.32%	30.87%	33.41%	28.82%	36.49%	48.82%	39.02%	-
Selling, General & Admin	51.51M	66.32M	78.69M	93.41M	183.87M	215.83M	218.58M	263.37M	290.51M	284.13M
SG&A % of Revenue	36.47%	34.18%	29.12%	25.5%	27.42%	26.93%	34.57%	41.51%	39.35%	-
Research & Development	8.67M	15.77M	19.45M	19.66M	34.27M	43.94M	42.72M	43.2M	54.18M	54.77M
R&D % of Revenue	6.14%	8.13%	7.2%	5.37%	5.11%	5.48%	6.76%	6.81%	7.34%	-
Other Operating Expenses	0	262K	0	0	5.87M	-28.73M	-30.57M	3.19M	-56.64M	-2M
Operating Income	14.01M▲ 0%	25.99M▲ 85.6%	40.08M▲ 54.2%	81.29M▲ 102.8%	167.25M▲ 105.7%	224.67M▲ 34.3%	47.7M▼ 78.8%	-35.11M▼ 173.6%	59.58M▲ 269.7%	66.57M▲ 0%
Operating Margin %	9.92%	13.39%	14.83%	22.19%	24.94%	28.03%	7.54%	-5.53%	8.07%	8.72%
Operating Income Growth %	-12.33%	85.56%	54.24%	102.8%	105.75%	34.33%	-78.77%	-173.61%	269.67%	-
EBITDA	24.46M	41.77M	60.95M	108.36M	205.7M	281.68M	133.82M	51.45M	138.32M	155.46M
EBITDA Margin %	17.32%	21.53%	22.55%	29.58%	30.68%	35.14%	21.16%	8.11%	18.74%	20.37%
EBITDA Growth %	14.78%	70.77%	45.93%	77.77%	89.84%	36.94%	-52.49%	-61.55%	168.86%	132.55%
D&A (Non-Cash Add-back)	10.45M	15.78M	20.87M	27.07M	38.45M	57.01M	86.11M	86.56M	78.75M	88.89M
EBIT	13.69M	25.99M	35.44M	71.35M	164.82M	220.3M	59.21M	-6.3M	85.56M	88.41M
Net Interest Income	-6.44M	-6.71M	-9.29M	-10.39M	-12.54M	4M	-10.03M	-22.57M	4.4M	-5.55M
Interest Income	0	0	0	1.74M	176K	6.98M	0	0	27.57M	27.24M
Interest Expense	6.44M	6.71M	9.29M	12.13M	12.71M	2.98M	10.03M	22.57M	23.17M	33.55M
Other Income/Expense	-6.76M	-4.55M	-13.93M	-22.07M	-13.71M	-5.53M	9M	8.08M	2.81M	-9.01M
Pretax Income	7.25M▲ 0%	21.44M▲ 195.8%	26.15M▲ 22.0%	59.22M▲ 126.4%	153.54M▲ 159.3%	219.14M▲ 42.7%	56.71M▼ 74.1%	-27.04M▼ 147.7%	62.38M▲ 330.7%	56.21M▲ 0%
Pretax Margin %	5.13%	11.05%	9.68%	16.17%	22.9%	27.34%	8.97%	-4.26%	8.45%	7.36%
Income Tax	-21.11M	4.82M	4.74M	-709K	25.25M	33.18M	21.11M	-1.52M	13.49M	4.82M
Effective Tax Rate %	-291.18%	22.48%	18.13%	-1.2%	16.45%	15.14%	37.23%	5.63%	21.62%	8.57%
Net Income	28.35M▲ 0%	16.62M▼ 41.4%	21.41M▲ 28.8%	59.93M▲ 179.9%	128.29M▲ 114.1%	185.96M▲ 45.0%	35.6M▼ 80.9%	-25.51M▼ 171.7%	48.89M▲ 291.6%	51.4M▲ 0%
Net Margin %	20.07%	8.56%	7.92%	16.36%	19.13%	23.2%	5.63%	-4.02%	6.62%	6.73%
Net Income Growth %	142.73%	-41.39%	28.85%	179.88%	114.08%	44.95%	-80.86%	-171.68%	291.64%	323.66%
Net Income (Continuing)	28.35M	16.62M	21.41M	59.93M	128.29M	185.96M	35.6M	-25.51M	48.89M	51.4M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	0.72▲ 0%	0.37▼ 48.6%	0.44▲ 18.9%	1.11▲ 152.3%	2.24▲ 101.8%	3.24▲ 44.6%	0.63▼ 80.6%	-0.46▼ 173.0%	0.86▲ 287.0%	0.91▲ 0%
EPS Growth %	111.76%	-48.61%	18.92%	152.27%	101.8%	44.64%	-80.56%	-173.02%	286.96%	842.57%
EPS (Basic)	0.74	0.38	0.44	1.14	2.33	3.35	0.64	-0.46	0.87	-
Diluted Shares Outstanding	39.15M	45.47M	49.21M	53.89M	57.26M	57.45M	56.38M	55.94M	56.56M	56.67M
Basic Shares Outstanding	38.23M	43.77M	48.34M	52.55M	55.02M	55.46M	55.72M	55.94M	56.23M	56.35M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

RGEN Balance Sheet

Repligen Corporation (RGEN) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	242.78M	275.74M	641.83M	902.38M	931.68M	998.12M	1.11B	1.07B	1.14B	1.16B
Cash & Short-Term Investments	173.76M	193.82M	528.39M	717.29M	603.81M	623.76M	751.32M	757.36M	767.63M	784.53M
Cash Only	173.76M	193.82M	528.39M	717.29M	603.81M	523.46M	751.32M	757.36M	566.02M	582.65M
Short-Term Investments	0	0	0	0	0	100.3M	0	0	201.61M	201.88M
Accounts Receivable	27.74M	35.75M	43.67M	71.39M	117.42M	116.25M	124.16M	134.12M	158.59M	151.55M
Days Sales Outstanding	71.68	67.26	58.98	71.14	63.92	52.94	71.67	77.16	78.41	73.64
Inventory	39M	42.26M	54.83M	95.03M	184.49M	238.28M	202.32M	142.96M	170.46M	179.26M
Days Inventory Outstanding	212.33	179.47	151.6	201.76	241.12	251.49	208.65	145.03	159.27	213.97
Other Current Assets	1.38M	2.43M	12.13M	14.09M	19.27M	17.41M	19.92M	20.6M	27.14M	46.02M
Total Non-Current Assets	500.74M	498.88M	758.28M	1B	1.43B	1.53B	1.72B	1.76B	1.81B	1.77B
Property, Plant & Equipment	22.42M	32.18M	74.16M	92.05M	226.52M	315.7M	322.95M	333.12M	306.15M	287.11M
Fixed Asset Turnover	6.30x	6.03x	3.64x	3.98x	2.96x	2.54x	1.96x	1.90x	2.41x	2.49x
Goodwill	327.33M	326.74M	468.41M	618.3M	860.36M	855.51M	987.12M	1.03B	1.11B	1.11B
Intangible Assets	144.75M	135.44M	212.55M	287.1M	337.27M	360.62M	406.96M	397.9M	386.15M	368.19M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	6.23M	174K	238K	573K	615K	815K	1.28M	868K	4.91M	18.47M
Total Assets	120.41M▲ 0%	139.45M▲ 15.8%	1.4B▲ 904.0%	1.9B▲ 35.9%	2.36B▲ 23.9%	2.53B▲ 7.3%	2.83B▲ 11.8%	2.83B▼ 0.1%	2.95B▲ 4.2%	2.93B▲ 0%
Asset Turnover	1.17x	1.39x	0.19x	0.19x	0.28x	0.32x	0.22x	0.22x	0.25x	0.26x
Asset Growth %	-58.32%	15.81%	904.03%	35.91%	23.94%	7.35%	11.83%	-0.05%	4.24%	11.67%
Total Current Liabilities	25.21M	129.84M	48.31M	318.96M	375.26M	404.2M	164.94M	126.79M	135.83M	126.21M
Accounts Payable	7.28M	10.49M	11.43M	16.88M	36.2M	27.55M	19.56M	32.13M	30.01M	34.66M
Days Payables Outstanding	39.64	44.54	31.59	35.84	47.31	29.08	20.18	32.6	28.04	38.47
Short-Term Debt	0	103.49M	0	243.74M	255.26M	284.62M	69.45M	0	21.56M	21.07M
Deferred Revenue (Current)	960K	1.29M	5M	15.32M	14.68M	19.28M	17.07M	13.24M	14.61M	51.1M
Other Current Liabilities	9.56M	9.95M	19.85M	20.29M	42.15M	47.47M	29.64M	49.29M	25.91M	70.48M
Current Ratio	9.63x	2.12x	13.28x	2.83x	2.48x	2.47x	6.74x	8.41x	8.37x	8.37x
Quick Ratio	8.08x	1.80x	12.15x	2.53x	1.99x	1.88x	5.51x	7.28x	7.12x	7.12x
Cash Conversion Cycle	244.37	202.18	178.99	237.07	257.72	275.34	260.14	189.59	209.64	249.14
Total Non-Current Liabilities	126.76M	29.21M	292.03M	54.78M	233.03M	216.7M	701.4M	730.16M	707.74M	699.1M
Long-Term Debt	99.25M	0	232.77M	0	0	0	510.14M	525.57M	542.21M	666.55M
Capital Lease Obligations	0	0	27M	26.43M	102.49M	131.39M	126.58M	145.58M	126.18M	514.06M
Deferred Tax Liabilities	25.17M	25.09M	29.94M	27.03M	33.48M	23M	39.32M	22.77M	22.5M	80.97M
Other Non-Current Liabilities	2.34M	4.13M	2.33M	1.32M	97.05M	62.31M	25.35M	36.24M	15.32M	76.18M
Total Liabilities	151.97M	159.05M	340.35M	373.74M	608.29M	620.9M	866.34M	856.95M	843.57M	825.31M
Total Debt	99.25M	103.49M	263.32M	275.42M	366.05M	422.96M	711.8M	686.25M	689.95M	687.62M
Net Debt	-74.51M	-90.33M	-265.07M	-441.88M	-237.76M	-100.5M	-39.52M	-71.11M	123.93M	104.97M
Debt / Equity	0.17x	0.17x	0.25x	0.18x	0.21x	0.22x	0.36x	0.35x	0.33x	0.33x
Debt / EBITDA	4.06x	2.48x	4.32x	2.54x	1.78x	1.50x	5.32x	13.34x	4.99x	4.42x
Net Debt / EBITDA	-3.05x	-2.16x	-4.35x	-4.08x	-1.16x	-0.36x	-0.30x	-1.38x	0.90x	0.90x
Interest Coverage	2.13x	3.87x	3.81x	5.88x	12.96x	74.00x	5.91x	-0.28x	3.69x	2.64x
Total Equity	591.55M▲ 0%	615.57M▲ 4.1%	1.06B▲ 72.2%	1.53B▲ 44.3%	1.75B▲ 14.4%	1.91B▲ 9.2%	1.96B▲ 2.8%	1.97B▲ 0.4%	2.11B▲ 6.8%	2.11B▲ 0%
Equity Growth %	250.52%	4.06%	72.16%	44.29%	14.45%	9.18%	2.83%	0.4%	6.76%	19.89%
Book Value per Share	15.11	13.54	21.54	28.37	30.56	33.26	34.85	35.27	37.24	37.16
Total Shareholders' Equity	591.55M	615.57M	1.06B	1.53B	1.75B	1.91B	1.96B	1.97B	2.11B	2.11B
Common Stock	436K	439K	521K	548K	553K	556K	558K	561K	563K	564K
Retained Earnings	-31.51M	-15.57M	5.84M	65.77M	194.06M	397.27M	432.87M	407.35M	456.25M	464.58M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-6.36M	-11.89M	-15.03M	2.08M	-16.89M	-34.39M	-37.81M	-52.53M	-2.53M	-14.31M
Minority Interest	0	0	0	0	0	0	0	0	0	0

RGEN Cash Flow Statement

Repligen Corporation (RGEN) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	17.45M	32.77M	67.22M	62.63M	119.02M	172.08M	113.92M	175.39M	117.42M	117.42M
Operating CF Margin %	12.36%	16.89%	24.87%	17.1%	17.75%	21.47%	18.01%	27.65%	15.9%	-
Operating CF Growth %	132.03%	87.78%	105.11%	-6.83%	90.05%	44.59%	-33.8%	53.97%	-33.06%	19.52%
Net Income	28.35M	16.62M	21.41M	59.93M	128.29M	185.96M	41.58M	-25.51M	48.89M	51.4M
Depreciation & Amortization	10.51M	15.78M	20.87M	27.07M	38.45M	57.01M	68.08M	86.56M	96.96M	83.67M
Stock-Based Compensation	6.75M	10.19M	12.85M	17.01M	27.5M	27.32M	25.57M	48.07M	32.6M	16.36M
Deferred Taxes	-24.68M	71K	-624K	-3.99M	6.52M	-1.35M	2.32M	0	0	-2.17M
Other Non-Cash Items	4.04M	4.25M	15.33M	11.97M	20.39M	-27.01M	-15M	5.36M	-10.16M	36.17M
Working Capital Changes	-7.52M	-14.13M	-2.62M	-49.35M	-102.13M	-69.84M	-8.64M	60.92M	-50.88M	-46.39M
Change in Receivables	-6.89M	-6.1M	-5.68M	-20.89M	-46.52M	-3.6M	-3.31M	-14.03M	-17.16M	-4.06M
Change in Inventory	605K	-4.04M	-10.8M	-29.99M	-89.78M	-57.2M	40.97M	56.9M	-14.95M	-23.19M
Change in Payables	807K	2.27M	662K	2.46M	19.52M	-8.2M	-9.8M	12.9M	-4.15M	8.46M
Cash from Investing	-98.25M	-14.04M	-205.31M	-201.38M	-221.17M	-233.24M	-123.28M	-86.38M	-298.47M	-228.35M
Capital Expenditures	-5.45M	-14.04M	-18.5M	-22.45M	-71.28M	-84.83M	-36.22M	-25.68M	-23.52M	-25.35M
CapEx % of Revenue	3.86%	7.23%	6.85%	6.13%	10.63%	10.58%	5.73%	4.05%	3.19%	-
Acquisitions	-112.8M	0	-182.15M	-175.04M	-149.89M	0	-186.64M	-54.77M	-70.33M	-608K
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	450K	-3.4M	-4.65M	-3.89M	0	-48.4M	-2.73M	-5.94M	-4.37M	-3.51M
Cash from Financing	129.94M	3.41M	484.87M	305.92M	961K	-13.34M	248.96M	-82.9M	-15.21M	-15.72M
Debt Issued (Net)	0	-11K	163.48M	0	-21K	0	290.09M	-69.94M	0	0
Equity Issued (Net)	129.31M	0	320.71M	297.77M	3.88M	0	-14.39M	4.29M	0	-28.8M
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	-14.39M	0	0	-14.34M
Other Financing	636K	3.42M	677K	8.14M	-2.9M	-13.34M	-26.75M	-17.26M	-15.21M	13.08M
Net Change in Cash	51.53M▲ 0%	20.06M▼ 61.1%	343.58M▲ 1612.5%	179.88M▼ 47.6%	-113.48M▼ 163.1%	-80.36M▲ 29.2%	227.87M▲ 383.6%	6.03M▼ 97.4%	-191.33M▼ 3272.0%	-114.58M▲ 0%
Free Cash Flow	12M▲ 0%	18.73M▲ 56.1%	44.06M▲ 135.2%	36.28M▼ 17.7%	47.74M▲ 31.6%	38.74M▼ 18.9%	74.93M▲ 93.4%	142.49M▲ 90.2%	93.9M▼ 34.1%	104.35M▲ 0%
FCF Margin %	8.49%	9.65%	16.3%	9.91%	7.12%	4.83%	11.85%	22.46%	12.72%	13.67%
FCF Growth %	275.38%	56.15%	135.21%	-17.66%	31.58%	-18.86%	93.43%	90.16%	-34.1%	-12.85%
FCF per Share	0.31	0.41	0.90	0.67	0.83	0.67	1.33	2.55	1.66	1.66
FCF Conversion (FCF/Net Income)	0.62x	1.97x	3.14x	1.05x	0.93x	0.93x	3.20x	-6.87x	2.40x	2.03x
Interest Paid	2.44M	2.44M	1.48M	1.07M	0	1.03M	988K	6.07M	0	0
Taxes Paid	4.02M	4.05M	6.5M	10.28M	0	34.37M	26.96M	19.3M	0	0

RGEN Key Ratios

Repligen Corporation (RGEN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	7.46%	2.75%	2.56%	4.63%	7.82%	10.16%	1.84%	-1.3%	2.4%	2.46%
Return on Invested Capital (ROIC)	3.29%	3.74%	4.56%	6.48%	9.65%	10.14%	1.92%	-1.38%	2.16%	2.16%
Gross Margin	52.53%	55.7%	51.15%	53.06%	58.35%	56.85%	44.03%	43.29%	47.09%	51.53%
Net Margin	20.07%	8.56%	7.92%	16.36%	19.13%	23.2%	5.63%	-4.02%	6.62%	6.73%
Debt / Equity	0.17x	0.17x	0.25x	0.18x	0.21x	0.22x	0.36x	0.35x	0.33x	0.33x
Interest Coverage	2.13x	3.87x	3.81x	5.88x	12.96x	74.00x	5.91x	-0.28x	3.69x	2.64x
FCF Conversion	0.62x	1.97x	3.14x	1.05x	0.93x	0.93x	3.20x	-6.87x	2.40x	2.03x
Revenue Growth	35.1%	37.38%	39.28%	35.53%	83.08%	19.54%	-21.11%	0.33%	16.36%	17.36%

RGEN SEC Filings & Documents

Repligen Corporation (RGEN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 5, 2026·SEC

Material company update

Feb 24, 2026·SEC

Material company update

Jan 6, 2026·SEC

10-K Annual Reports

FY 2026

Feb 26, 2026·SEC

FY 2025

Mar 14, 2025·SEC

FY 2024

Feb 22, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 6, 2026·SEC

FY 2025

Nov 4, 2025·SEC

FY 2025

Aug 7, 2025·SEC

RGEN Frequently Asked Questions

Repligen Corporation (RGEN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Repligen Corporation (RGEN) reported $763.3M in revenue for fiscal year 2025. This represents a 6903% increase from $10.9M in 1996.

Repligen Corporation (RGEN) grew revenue by 16.4% over the past year. This is strong growth.

Yes, Repligen Corporation (RGEN) is profitable, generating $51.4M in net income for fiscal year 2025 (6.6% net margin).

Dividend & Returns

Repligen Corporation (RGEN) has a return on equity (ROE) of 2.4%. This is below average, suggesting room for improvement.

Repligen Corporation (RGEN) generated $104.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More RGEN

Repligen Corporation (RGEN) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Repligen Corporation(RGEN)Earnings, Financials & Key Ratios

RGEN Key Insights

✓Strengths

✗Weaknesses

RGEN Price & Volume

RGEN Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

RGEN Recent Earnings

RGEN Peer Comparison

Compare RGEN vs Peers

vs FTRE

vs TMO

Compare Top 5

RGEN Income Statement

RGEN Balance Sheet

RGEN Cash Flow Statement

RGEN Key Ratios

RGEN SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

RGEN Frequently Asked Questions

Explore More RGEN

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation